Glimmer of Hope provides just that to cancer patients
"The wedding celebration, all of it, is really important to be perfect," said Herzo.
With five months until they tied the knot, doctors diagnosed her with breast cancer.
"Then there's this punch in the gut that you get," she said.
Herzo went through chemotherapy at Saint Clair's Cancer Center, with UPMC Hillman Cancer Center.
"It was really, really hard," she said. "You don't feel great at all."
All through her treatment, she kept a wedding goal in mind.
"One of the most important things was to make sure I had hair on my head," Herzo said.
That's where this new scalp cooling therapy comes into play.
"Unfortunately, hair loss is something that's associated with the number of chemotherapies that we use, and so cooling caps have helped to try to minimize hair loss for patients going through chemotherapy," said St. Clair Hospital Cancer Center's Dr. Bob Vanderweele.
Patients wear a cap on their head to cool the temperature of their scalp during hours of chemotherapy. It takes hours, but the Amma Scalp Cooling system is portable, and it made more of Herzo's hair stay in place for her dream wedding.
Preventing hair loss is not vanity; it's emotional stability in the face of uncertainty.
"Definitely made a difference that way. I can't remember being sad at all at that time. It was like we were just going to push through," said Herzo.
Now with the non-profit Glimmer of Hope and St. Clair, it's at the hospital, in the South Hills.
"That's amazing, the time that I was going through treatment," Herzo said. "I definitely wanted to see more women take advantage of it. I'm incredibly thankful to them. That they helped make this happen."
It's also free for patients whose insurance won't cover it.
"We're thrilled with this cold cap project," said Glimmer of Hope found Diana Napper.
"We really try to support the patient completely through the journey, and obviously our goal is to cure," Napper said.
The cool cap helps hide cancer treatment and provides a sense of normalcy.
"I know a lot of women with kids say that they need to stay strong and look strong for their children," said Herzo.
It's more than just hair care; during cancer treatment, it's a "Glimmer of Hope" for breast cancer patients during the darkest moments of their lives.
Through fundraising and the donations from individuals, businesses, sports celebrities, and organizations, Glimmer of Hope's donated over $7,000,000 for breast cancer projects in our region.
The non-profit's helped at least a thousand patients, funded cancer-curing research, and more.
For more information on Glimmer of Hope, click here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
27 minutes ago
- Fast Company
Wegovy and Zepbound prices are dropping but steady access to the weight-loss drugs remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven. 'The medications should be available, the question is at what price and can people sustain that,' said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage. Doctors say the situation forces them to get creative in treating patients, but there's hope that prices may fall more in the future. The drugs are still in high demand Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity. Zepbound brought in $2.3 billion in U.S. sales during this year's first quarter, making it one of drugmaker Eli Lilly's best sellers. Novo Nordisk says Wegovy has about 200,000 weekly prescriptions in the U.S., where it brought in nearly $1.9 billion in first-quarter sales. Insurance coverage is increasing — for some The benefits consultant Mercer says more businesses with 500 or more employees are adding coverage of the injected drugs for their workers and family members. And Novo says 85% of its patients who have coverage in the U.S. pay $25 or less per month. Plus some patients with diabetes can get coverage of the GLP-1 drugs Ozempic and Mounjaro from Novo and Lilly that are approved to treat that condition. But most state and federally funded Medicaid programs don't cover the drugs for obesity and neither does Medicare, the federal program mainly for people age 65 and older. Even the plans that cover the drugs often pay only a portion of the bill, exposing patients to hundreds of dollars in monthly costs, said Dr. Beverly Tchang. Drugmakers offer help with these out-of-pocket costs, but that assistance can be limited. 'Coverage is not the same as access,' said Tchang, a New York-based doctor who serves as a paid advisor to both Novo and Lilly. But coverage remains inconsistent Bill-payers like employers are nervous about drugs that might be used by a lot of people indefinitely. Some big employers have dropped coverage of the drugs due to the expense. Pharmacy benefit managers, or PBMs, also are starting to pick one brand over the other as they negotiate deals with the drugmakers. One of the nation's largest PBMs, run by CVS Health, dropped Zepbound from its national formulary, or list of covered drugs, on July 1 in favor of Wegovy. That forced Tchang to figure out another treatment plan for several patients, many of whom took Zepbound because it made them less nauseous. Dr. Courtney Younglove's office sends prospective patients a video link showing them how to check their insurer's website for coverage of the drugs before they visit. 'Then some of them just cancel their appointment because they don't have coverage,' the Overland Park, Kansas, doctor said. Cheaper compounded drugs are still being sold Compounding pharmacies and other entities were allowed to make off-brand, cheaper copies of Wegovy and Zepbound when there was a shortage of the drugs. But the U.S. Food and Drug Administration determined earlier this year that the shortage had ended. That should have ended the compounded versions, but there is an exception: Some compounding is permitted when a drug is personalized for the patient. The health care company Hims & Hers Health offers compounded doses of semaglutide, the drug behind Wegovy, that adjust dose levels to help patients manage side effects. Hims says these plans start at $165 a month for 12 months, with customers paying in full upfront. It's a contentious issue. Eli Lilly has sued pharmacies and telehealth companies trying to stop them from selling compounded versions of its products. Novo recently ended a short-lived partnership with Hims to sell Wegovy because the telehealth company continued compounding. Novo says the compounded versions of its drug put patient safety at risk because ingredients are made by foreign suppliers not monitored by US regulators. Hims says it checks all ingredients to make sure they meet U.S. quality and safety standards. It also uses a third-party lab to verify that a drug's strength is accurately labeled. Prices have dropped Both drugmakers are selling most of their doses for around $500 a month to people without insurance, a few hundred dollars less than some initial prices. Even so, that expense would eat up about 14% of the average annual per person income in the U.S., which is around $43,000. There are some factors that may suppress prices over time. Both companies are developing pill versions of their treatments. Those could hit the market in the next year or so, which might drive down prices for the older, injectable doses. Younglove said some of her patients save as much as 15% by getting their doses shipped from a pharmacy in Canada. They used to get them from an Israeli pharmacy until the Canadians dropped their prices. She says competition like this, plus the introduction of pill versions, will pressure U.S. prices. 'I think price wars are going to drive it down,' she said. 'I think we are in the early stages. I have hope.' The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.
Associated Press
28 minutes ago
- Associated Press
American kids have become increasingly unhealthy over nearly two decades, new study finds
The health of U.S. children has deteriorated over the past 17 years, with kids today more likely to have obesity, chronic diseases and mental health problems like depression, a new study says. Much of what researchers found was already known, but the study paints a comprehensive picture by examining various aspects of children's physical and mental health at the same time. 'The surprising part of the study wasn't any with any single statistic; it was that there's 170 indicators, eight data sources, all showing the same thing: a generalized decline in kids' health,' said Dr. Christopher Forrest, one of the authors of the study published Monday in the Journal of the American Medical Association. Health Secretary Robert F. Kennedy Jr. has brought children's health to the forefront of the national policy conversation, unveiling in May a much-anticipated 'Make America Healthy Again' report that described kids as undernourished and overmedicated, and raised concerns about their lack of physical activity. But the Trump administration's actions — including cuts to federal health agencies, Medicaid and scientific research — are not likely to reverse the trend, according to outside experts who reviewed Monday's study. 'The health of kids in America is not as good as it should be, not as good as the other countries, and the current policies of this administration are definitely going to make it worse,' said Dr. Frederick Rivara, a pediatrician and researcher at the Seattle Children's Hospital and UW Medicine in Seattle. He co-authored an editorial accompanying the new study. Forrest and his colleagues analyzed surveys, electronic health records from 10 pediatric health systems and international mortality statistics. Among their findings: The research points to bigger problems with America's health, said Forrest, who is a pediatrician at the Children's Hospital of Philadelphia. 'Kids are the canaries in the coal mine,' he said. ' When kids' health changes, it's because they're at increased vulnerability, and it reflects what's happening in society at large.' The timing of the study, he said, is 'completely fortuitous.' Well before the 2024 presidential election, Forrest was working on a book about thriving over the life span and couldn't find this sort of comprehensive data on children's health. The datasets analyzed have some limitations and may not be applicable to the full U.S. population, noted Dr. James Perrin, a pediatrician and spokesman for the American Academy of Pediatrics, who wasn't involved in the study. 'The basic finding is true,' he said. The editorial published alongside the study said while the administration's MAHA movement is bringing welcome attention to chronic diseases, 'it is pursuing other policies that will work against the interests of children.' Those include eliminating injury prevention and maternal health programs, canceling investments in a campaign addressing sudden infant death and 'fueling vaccine hesitancy among parents that may lead to a resurgence of deadly vaccine-preventable diseases,' authors wrote. Officials from the U.S. Health and Human Services Department did not respond to a request for comment. Forrest said risks highlighted by the MAHA report, such as eating too much ultra-processed food, are real but miss the complex reality driving trends in children's health. 'We have to step back and take some lessons from the ecological sustainability community and say: Let's look at the ecosystem that kids are growing up in. And let's start on a kind of neighborhood-by-neighborhood, city-by-city basis, examining it,' he said. ____ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Associated Press
42 minutes ago
- Associated Press
Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
Illustration of TAT Alfa Cytology has announced RDC development services supported by In Vivo studies in radiopharmaceuticals. Alfa Cytology, a leading-edge biotech company engaged in cancer research, has released its services on robust RDC (Radionuclide Drug Conjugate) development technical support for radiopharmaceuticals. The services are specifically designed to transform the radiopharmaceutical industry, enhancing quality and precision for disease diagnosis and therapy. The oncology and diagnostic imaging fields are rapidly expanding, with an increasing need for transformative approaches to medical research and treatment. As current methods in disease diagnosis and treatment often lack the specificity, sensitivity, and customization demanded by the cutting edge of diagnostic medicine and theranostics, Alfa Cytology has developed the platform to meet the individualized needs of its clients. This takes a highly individualized approach, accounting for the specific biochemical and kinetic characteristics of the large variety of radiotracers and therapeutics in use. Alfa Cytology's expert services can be leveraged for the custom synthesis, optimization, and quality control of radiopharmaceuticals, to a standard of safety and efficacy unequaled by other service providers. An essential component is in vivo studies in radiopharmaceuticals. These studies, which give critical insights into the in vivo interactions and pharmacodynamics of radiopharmaceuticals, form the backbone of a rigorous approach to therapeutic radiopharmaceutical development. The research is supported by an extensive imaging and analytical infrastructure, enabling researchers to better understand the biodistribution, safety, pharmacokinetics, and overall therapeutic potential of next-generation radiopharmaceutical agents. The in vivo research option is a critical tool in efforts to develop more targeted and individualized radiopharmaceutical therapeutics and diagnostics. Alfa Cytology offers a wide range of technical support options and expert services for research teams, including custom synthesis of radiotracers, radionuclide production, labeling methodologies, and advanced analytical support to maximize radiochemical purity, as well as radioanalytical support and method development. Alfa Cytology continues to expand its service offerings and is continuously updating its highly experienced technical teams to meet the increasingly complex demands of the research community and to continue to be a resource for innovation and development in diagnostic imaging and cancer therapy. Alfa Cytology provides a fully integrated infrastructure to leverage RDC services and take advantage of cutting-edge in vivo research, connecting the laboratory to the real world. About Alfa Cytology Alfa Cytology, headquartered in New York, is a CRO company, offering state of the art solutions in radiopharmaceutical R&D. Alfa Cytology's team of industry veterans have assembled a set of broad integrated skills in molecular imaging, radiochemistry, and regulatory sciences, which allow them to provide next-generation services across the broad range of research needs within the community. For more information on the newest tools and solutions in radiopharmaceuticals, visit our service pages to learn how Alfa Cytology is redefining the future of cancer research and nuclear medicine. Media Contact Company Name: Alfa Cytology Contact Person: Thassia C. Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
